Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Gold & silver

Small Cap Watch: Key operational and commercialisation updates

The S&P/ASX Small Ordinaries (XSO) lost 0.81% yesterday to land at 3,231.20. Over the past five days, the index is down 0.73%.

Quarterly reports are now trickling in and will soon dominate the news, however, there’s still plenty happening among small caps. Several have reported key operational and commercialisation updates, spanning exploration, clinical trials, product sales and advanced materials processing.

Yandal Resources progresses large-scale Caladan drilling

Yandal Resources Ltd has received the first batch of assay results from its extensive air-core (AC) drilling program at the Caladan target, initiated in early June. The latest fire assay results cover 16 AC holes totalling 1,685 metres. To date, 100 holes have been drilled (10,200 metres), with a further 25 holes remaining. The full campaign will cover 12,500 metres across ten drill lines over a 6.4-kilometre strike length.

Orthocell achieves first US sales for Remplir™

Orthocell Ltd has recorded its first sales revenue in the United States for its Remplir™ nerve repair device. This milestone follows the product’s first surgical use on 26 June 2025 and subsequent early cases, marking a significant step in entering the US$1.6 billion US peripheral nerve repair market.

Race Oncology receives HREC approvals for RC220 trial

Race Oncology Ltd has secured Human Research Ethics Committee (HREC) approvals from the University of Hong Kong to initiate its Phase 1 clinical trial (RAC-010) of RC220 in combination with doxorubicin. The trial will be conducted at Queen Mary and Prince of Wales Hospitals. Department of Health approval has been received for Queen Mary, with the second expected in the coming weeks. Site activations are scheduled for late July to mid-August 2025.

Green360 begins bulk calcining of high-purity kaolin

Green360 Technologies Ltd has commenced a bulk calcining campaign of 457.7 tonnes of high-purity kaolin from its wholly owned Pittong Operation. The processed material will yield advanced, high-reactivity metakaolin, supporting the company’s transition into value-added material production.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK